

# Ellen R Copson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1913800/publications.pdf>

Version: 2024-02-01

28  
papers

889  
citations

566801

15  
h-index

580395

25  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1654  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of race and ethnicity in breast cancer disparities and implications for precision oncology. BMC Medicine, 2022, 20, 72.	2.3	33
2	Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. British Journal of Surgery, 2022, 109, 800-803.	0.1	5
3	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	1.0	7
4	176 Clinical research participation in neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A63.3-A63.	0.9	0
5	Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast carcinoma. Scientific Reports, 2022, 12, .	1.6	7
6	Cancer survivorship, excess body fatness and weight-loss intervention where are we in 2020?. British Journal of Cancer, 2021, 124, 1057-1065.	2.9	29
7	Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK Alert Level 4 phase of the B-MaP-C study. British Journal of Cancer, 2021, 124, 1785-1794.	2.9	21
8	A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 241-257.	1.0	41
9	Ethnicity and breast cancer in the UK: Where are we now?. European Journal of Surgical Oncology, 2021, 47, 2978-2981.	0.5	7
10	TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status. British Journal of Surgery, 2021, 108, .	0.1	0
11	The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol. International Journal of Surgery Protocols, 2020, 24, 1-5.	0.5	9
12	Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer. JCO Precision Oncology, 2020, 4, 472-485.	1.5	14
13	Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients. British Journal of Cancer, 2020, 122, 1618-1629.	2.9	23
14	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology and Therapeutics, 2020, 108, 661-670.	2.3	17
15	A Context-Specific Digital Alcohol Brief Intervention in Symptomatic Breast Clinics (Abreast of) Tj ETQq1 1 0.784314 rgBT /Oyerlock 10	0.5	10
16	Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. Supportive Care in Cancer, 2019, 27, 297-309.	1.0	11
17	The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast clinics. BMJ Open, 2019, 9, e027371.	0.8	31
18	Alcohol use and breast cancer risk: A qualitative study of women's perspectives to inform the development of a preventative intervention in breast clinics. European Journal of Cancer Care, 2019, 28, e13075.	0.7	18

#	ARTICLE	IF	CITATIONS
19	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. <i>Breast</i> , 2019, 45, 1-6.	0.9	21
20	Genetic testing for young women with breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e183.	5.1	0
21	Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 169-180.	5.1	316
22	Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study. <i>Breast Cancer Research</i> , 2018, 20, 19.	2.2	18
23	Clinical proteomics and breast cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2015, 13, 271-278.	0.8	28
24	Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 978-988.	3.0	156
25	Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. <i>BMC Cancer</i> , 2006, 6, 80.	1.1	37
26	Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). <i>Clinical Evidence</i> , 2006, , 30-44.	0.2	0
27	Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). <i>Clinical Evidence</i> , 2005, , 1-18.	0.2	0
28	Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy. <i>BJU International</i> , 2004, 94, 552-558.	1.3	23